- This week we have not registered any new major short campaigns.
- Despite the overall low activity we have noted several updates and follow-ups. Hindenburg is apparently sued by EBIX, Culper points out the supposed crypto irony and Jehoshaphat sees confirmation of their thesis at AMRC. All mentioned stocks are already down, but activists likely see further opportunity.
- Lastly, we are tracking the most recent stock price gyrations at several previous targets. We feature a strong rebound in a China-based EV business, and one failed and one failing biotech stocks.
Save time and ask us for independent short thesis verification. Get our custom support. Contact Breakout Point!
Bits and Pieces
- Our H1 Activist Short Sellers report is out
- Follow-up by Culper on popular retail stock, Veru
- Interesting "anchoring bias" admission on short selling by Coatue:
"Never easy to short stocks already down 50%+ from highs" pic.twitter.com/IyE52fPNXs— Eric Newcomer (@EricNewcomer) July 6, 2022
This week we saw several stocks that moved in the right direction for the short-sellers. Yet again, among the biggest movers was Enochian Biosciences (ENOB) which dropped another 6% in the past week. This biotech was recently targeted by Hindenburg Research due to allegations of dubious management. Most importantly, the report believed the co-founder and key asset of the company is a fraud and a repeat felon. As per Hindenburg, the co-founder does not seem to have any medical degree despite touting many pre-clinical assets which have been licensed to ENOB from co-founder-controlled entities among other things. According to the activist, the co-founder siphoned over $20m from shareholders over the years. We would also like to point out work by Sharesslueth on ENOB that they publiched on the same day as Hindenburg:
A not-so-quick story.— Caleb Hannan (@calebhannan) June 1, 2022
In March this video appeared. It shows pictures of me, my wife, and the home we share with our kids.
I can't definitely prove that the person who created it was arrested last week for hiring a hitman who killed a father of seven in Vermont. But I'll try. pic.twitter.com/I6cfjtlR96
We highlighted ENOB last week as the stock got hit by a flurry of bad news. This time around it seems the market is simply accepting that the stock might not be so quickly recovering from all the allegations created by associating with the co-founder of EBON. There was no news suggesting anything different.
On the other side of the tracks, there were several movements against short-sellers. One of the most significant surges was seen in Faraday Future (FFIE) which went up 52% this week. This China-based EV company was targeted by J Capital due to allegations of dubious business model and questionable corporate governance.
Most importantly, the report believed the company is likely to yet again postpone its EV launch. As per activist, FFIE has constantly pushed the deadline further. Now it is being sued by a slew of unpaid suppliers and apparently, the Chinese court froze some of its assets. FFIE talked about having over 14,000 pre-orders, but earlier this year it quietly dropped this number.
The thesis has largely played out as the stock ended a protracted downside trend without much hope for a rebound. However, just in the past week, the stock became a favourite among the short-squeeze crowd due to the technical setup. This has led to a sharp increase in the stock. There does not seem to be any fundamental news that would invalidate JCap's initial research. The stock is down only 28% since the activist raised the red flags late last year.
Another stock which went against the short-seller thesis was Mesoblast (MESO) which is up about 20% in the past five days. Initially, it was Alpha Exposure who targeted this biotech due to allegations of obfuscation and inefficient products in the pipeline.
Most importantly, the report believed the company mistreated the proper guidance for statistical analysis when it comes to the endpoints for MESO's key trial. This is likely to further support the notion that the trial will not be accepted and will have to be re-run. This could cause significant cash issues as the previous Phase 3 has run six years.
The thesis has worked out as the stock was down over 80% at one point, but now MESO is made somewhat of a comeback. It is not clear why. The market sold the stock after earnings and the company has been quiet regarding new business developments. Twitter chatter is mostly confined to technical analysis.
Stocks are down, but activists see further downside opportunity
This week we also saw several activists post updates about their campaigns. All of these stocks are already down, but given the updates, further downside is seems to be on activists' radars...
(Stay on top of short selling developments - Join Breakout Point).
FAQ | Q: Can I publish parts of the above data and analytics in an article? A: As long as you reference our work - yes, you can.
FAQ | Q: Could you provide more related data and analytics? A: Sure, contact us, and we'll try to help as soon as possible.
* Note: Presented data and analytics is as of available on 2022-07-09 UTC 10:00.
The services and any information provided by Breakout Point or on the Breakout Point website shall not be or construed to be any advice, guidance or recommendation to take, or not to take, any actions or decisions in relation to any investment, divestment or the purchase or sale of any assets, shares, participations or any securities of any kind. Any information obtained through Breakout Point and its services should never be used as a substitute for financial or other professional advice. Any decisions based on, or taken by use of, information obtained through Breakout Point and by its services are entirely at own risk.